SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network ($AVT.X) is gaining traction, with community members highlighting its strong chart setup and real-world partnerships (Vodafone, Heathrow airport, and DOT) and potential for a breakout. The token's low market cap and integration with Polkadot are also sparking interest, as some believe it is undervalued with significant upside. Traders are closely watching volume as a key indicator for potential price movement.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU.X is trending as the community rallies around its strong holder growth and IRL initiatives, including a recent CoinMarketCap Boost competition win. Talk centers on its dedicated community, a new energy drink flavor, and upcoming businesses, reinforcing bullish sentiment. The project's unique brand-building efforts and increasing holder count are attracting attention.

Nyvo is a cutting-edge platform that allows anyone to create fully functional decentralized applications (dApps) using simple natural language prompts. In other words, users describe the app they want in plain English, and Nyvo’s AI-driven engine automatically generates both the on-chain smart contract backend and the web-based frontend, delivering a live blockchain application within minutes. This “prompt-to-dApp” approach dramatically lowers the barriers to Web3 development by removing the need to write code or navigate complex developer tools.The result is that developers, entrepreneurs, and even non-technical users can go from an idea to a deployed dApp faster and easier than ever before.

Nyvo

Nyvo ($NYVO.X) is gaining traction, with community members highlighting bullish chart patterns and anticipating a breakout. The coin is being described as a potential 'moonshot,' with many urging others to buy in early before a significant price increase. Conversations suggest growing excitement around its potential.

English version Introducing SWFTCoin (SWFTC) $SWFTC: Powering SWFT Blockchain and AI Services (SWFTGPT)  SwftCoin ($SWFTC) is the native utility token driving SWFT Blockchain's AI-powered ecosystem, SWFTGPT, and the first ever AI token featured on Coinbase. SWFTGPT is also the first domain-specific LLM for crypto.  SwftCoin key features include: 50% Reduced Transaction Fees: Lower costs on all transactions. AI Service Payments: Use $SWFTC to access SWFTGPT. Tools include expert market analysis,  predictions, and intelligent trading solutions.  Membership Benefits: Unlock premium features and AI agent services within SWFTGPT. AI-Powered Swaps: Enable precise, fast cross-chain transactions and analytics. SWFT Blockchain combines AI innovation with blockchain infrastructure, simplifying crypto trading while enhancing functionality through $SWFTC.   Chinese version $SWFTC：驱动 SWFT Blockchain 和 AI 服务（SWFTGPT） SwftCoin ($SWFTC) 是 SWFT Blockchain 的原生实用代币，为其 AI 驱动的生态系统 SWFTGPT 提供支持，同时也是 Coinbase 上首个 AI 代币。SWFTGPT 也是首个专注于加密领域的特定领域大型语言模型 (LLM)。 SwftCoin 的主要功能包括： 1、50% 交易费减免：降低所有交易成本。 2、AI 服务支付：使用 $SWFTC 访问 SWFTGPT 工具，包括专家市场分析、预测以及智能交易解决方案。 3、会员权益：解锁 SWFTGPT 的高级功能和 AI 代理服务。 4、AI 驱动的闪兑：实现精准快速的跨链交易和数据分析。 SWFT Blockchain 将 AI 创新与区块链基础设施结合，通过 $SWFTC 简化加密交易，并提升其功能性。

SwftCoin

SwftCoin is trending as the community discusses potential catalysts and its future prospects, with some anticipating a significant price movement. Community members are debating whether the current price action represents a buying opportunity or a continuation of existing trends, while also pointing to the fully diluted coin supply. Discussions also mention the long-term potential related to AI integration and cross-chain swap functionality.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as community members celebrate its long-term presence on the Solana network and highlight its strong community. The project's unique branding and joke-meta approach are also sparking interest, with some comparing it to early $DOGE.X. Community members are actively promoting its availability on $JUP.X.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks is trending as discussions revolve around store closures, layoffs, and the effectiveness of its 'Back to Starbucks' plan amid increasing competition from chains like Dutch Bros and Luckin Coffee. Community members are sharing store experiences and debating whether recent moves will revive growth, with some highlighting concerns about valuation and market share. The leadership's strategies are under scrutiny, particularly in light of shifting consumer preferences and evolving dynamics in the coffee industry.

TON Strategy Co. engages in platform development. The firm's Software-as-a-Service (SaaS) platform is based on its proprietary interactive video technology and consists of a suite of sales enablement business software products offered on a subscription basis. The company was founded by Rory J. Cutaia on November 27, 2012 and is headquartered in Las Vegas, NV.

TON Strategy Co.

TON Strategy Co. ($TONX) is trending as discussions revolve around its strategic shift towards Toncoin and integration with Telegram, with some seeing it as a bold move and others expressing skepticism. Community members are debating the potential for growth within the Telegram ecosystem and the company's overall direction, while some critics are pointing to past performance and management's history. The stock's volatility and connection to the crypto market are also being closely watched.

Linea is the Layer 2 built from first principles to strengthen Ethereum and the entire ETH economy. Every aspect of its design—from its productive ETH burn mechanics, and capital efficient native yield, to its underlying Ethereum-equivalent zk tech—amplifies the value and utility of Ethereum Mainnet. All of this is backed by the largest ecosystem fund in the space, managed by the most trusted Ethereum builders. With institutional-grade infrastructure, and deep integration across DeFi, Linea is the best chain for ETH capital, where every transaction and every block strengthens Ethereum. Linea is where Ethereum wins.

Linea

Linea is trending as the community discusses its potential integration with SWIFT, a global banking network, which some believe could challenge existing cross-border payment solutions. The news has sparked excitement, with many viewing it as a significant validation of blockchain technology. Speculation is growing around potential price movements and the impact on related cryptocurrencies like ETH and XRP.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Helium is trending as the community discusses its potential following news and signals, while others express concerns about its tokenomics and profitability for miners. Conversations also focus on Helium's relationship with Solana and its possible growth catalysts amid the broader DePIN sector narrative. Community sentiment appears mixed, with some anticipating a breakout and others remaining bearish.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

$GASS.X is trending as the community draws comparisons to $PEPE.X, noting shared ties to creator Matt Furie and anticipating similar growth potential. Community members are actively discussing accumulation strategies, holding for long-term gains, and the possibility of new exchange listings to fuel further momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?

Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.

Shares of Immuneering Corp. rose 42% in after-hours trading on Wednesday after the company’s Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel showed an 86% overall survival rate in patients with first-line pancreatic cancer at nine months, compared with a 47% benchmark for standard of care.The stock closed Wednesday’s regular session up 7.5% at $9.23.Immuneering said it plans to seek regulatory feedback on its pivotal trial plans in the fourth quarter and, subject to that feedback, aims to launch a Phase 3 trial of atebimetinib plus mGnP by the end of 2025, with patient dosing to begin by mid-2026.&nbsp;The company also expects to initiate additional atebimetinib clinical trial combination arms in 2026, including in non-small cell lung cancer.Progression-free survival at nine months was 53%, compared to a 29% benchmark for standard of care. At six months, overall survival was 94%, and progression-free survival was 70%, both&nbsp;rates exceeding&nbsp;historical benchmarks. Median overall survival has not yet been reached.The treatment was generally well-tolerated. The serious side effects,&nbsp;observed in more than 1 in 10 people, included low white blood cell counts, which can increase the risk of infection, and anemia, characterized by low red blood cell levels. No new safety concerns were identified.CEO Ben Zeskind said the nine-month overall survival data widened the gap against&nbsp;the standard of care, describing the results as “extraordinary.” Chief Scientific Officer Brett Hall said atebimetinib, designed as a Deep Cyclic Inhibitor, represents a “fundamental shift in targeted therapy.”&nbsp;Vincent Chung, principal investigator of the trial at City of Hope, said the results mark “an important step” toward urgently needed new treatment options for pancreatic cancer, adding that the company is also planning a confirmatory study.&nbsp;Separately, Immuneering announced a proposed underwritten public offering of its Class A common stock, or in lieu of stock, pre-funded warrants. The company also stated that Sanofi agreed to purchase $25 million of shares in a concurrent private placement at the public offering price, with both transactions expected to close simultaneously.&nbsp;Immuneering plans to use the proceeds to advance the development of its drug candidates and for general corporate purposes.On Stocktwits, retail sentiment for Immuneering was ‘extremely bullish’ amid a 3,540% surge in 24-hour message volume, placing it among the top 10 trending equities on the platform.&nbsp;One user said the offering “didn’t completely kill the momentum,” adding that it gave them hope for the next trading day.&nbsp;<stembedurl>https://stocktwits.com/Mushichka/message/629894873</stembedurl>Another user said they were in “for the long haul, which now extends into mid-2026,” and added that the stock offering would likely be shrugged off within a day before analysts begin calculating Immuneering’s valuation based on potential sales of what they described as the gold standard for treating pancreatic cancer.<stembedurl>https://stocktwits.com/OptimistJP/message/629894127</stembedurl><a href="https://stocktwits.com/symbol/IMRX">Immuneering’s stock</a> has surged 320% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Immuneering’s stock (IMRX) has surged 320% so far in 2025. (Photo credit: Getty Images)

Why Immuneering Stock Soared Over 40% After-Hours Today

Updated trial data showed its drug atebimetinib nearly doubled survival benchmarks in first-line pancreatic cancer, with the company planning a pivotal Phase 3 study by late 2025.

Equity

SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU

Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.

FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing

The FDA extends SNY's tolebrutinib NDA review by three months, with decision now expected on Dec. 28, 2025.

Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock?

RIGL shares surge 77% in three months as Tavalisse drives record sales along with other products while boosting the company's 2025 outlook.

REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?

Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.

SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag

Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.

Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?

RIGL's top line keeps growing on strong sales momentum for lead product, Tavalisse, while other products support growth.

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.

SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study

Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Current Price	$45.87
Prev Close	$45.07
Open	$45.46
Dividend Yield	3.31%
50-Day Moving Average	$48.24
Beta	0.28
Avg. Volume	2.33M
PE Ratio	11.32

52-Week High	$60.12
52-Week Low	$44.73
Market Capitalization	$110.83B
EPS (Annual)	$2.40
Price to Book	1.35
Revenue Per Employee	$525,340.04
Enterprise Value/EBITDA	N/A

SNY
Sanofi-Aventis

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SNY News

SNY Sanofi-Aventis